Botanix Pharmaceuticals Limited

ASX:BOT

Botanix Pharmaceuticals Limited

ASX:BOT
TradeAdd trade order Follow Unfollow Set Price Alert
$0.120 (-4%)
Last close price
#29
Rank
40
Held by
65
Followers
TradeAdd trade order Follow Unfollow Set Price Alert
Reports (2) My Report Forum Investors
Forum Topics BOT BOT Ecclock Marketing Auth - Korea

Pinned straw:
Arizona
Added 3 months ago

Not huge news but should bring in a little royalty revenue, when its up and running....


Approval for Marketing Authorization for ECCLOCK gel 5% in Korea

for Treatment of Primary Axillary Hyperhidrosis

Kaken Pharmaceutical Co., Ltd. (“Kaken”, head office: Bunkyo-ku, Tokyo; President and

Representative Director, Hiroyuki Horiuchi) announced that Dong-Wha Pharm. Co., Ltd.

(“Dong Wha”, head office: Seoul; Co-CEOs, Jun Ha Yoo and In Ho Yoon) has obtained

approval from MFDS: Ministry of Food and Drug Safety for the marketing authorization in

Korea of ECCLOCK gel 5%, a topical formulation drug for primary axillary hyperhidrosis

(generic name: sofpironium bromide; product name in Japan: ECCLOCKⓇ).

In June 2023, Kaken and Dong Wha entered into an agreement under which Kaken granted

Dong Wha the exclusive right for the development and commercialization of the product in

Korea based on its rights to sub-license in certain Asian countries granted by Botanix SB, Inc.

(head office: Pennsylvania, USA), and Dong Wha had applied for marketing authorization for

Sofpironium Bromide. Dong Wha plans to launch the product at the earliest possible timing.

About Dong Wha

Dong Wha is a Korean pharmaceutical company, listed on the Korean Stock Exchange

(000020.KS), with strong capabilities in research and development, manufacturing and

marketing and has been providing superior pharmaceutical products in Korea since its

foundation in 1897. For more information, please visit https://www.dong-wha.co.kr/.
Schwerms
Added 3 months ago

Every little bit helps..

Wonder how much trickles through when it's a royalty on a royalty.

E.g Kaken get 10% of net sales then we get 5% of krakens 10%?

15
Arizona
Added 3 months ago

@Schwerms Take it with a grain of salt but...A quick google came up with the following Ai answer:


Botanix will make money from Korean Ecclock (sofpironium bromide gel 5%) sales through its sublicense agreement with Kaken, receiving 25% of royalties and milestone payments that Kaken receives from the Korean sub-licensee Dong Wha Pharm, although the exact forecast amount is not known at this time. 

How the Payment Structure Works

  1. 1. Sublicense Agreement:
  2. Botanix has a sublicense agreement with Kaken, the Japanese licensee and marketer of Ecclock. 
  3. 2. Korean Out-licensing:
  4. Kaken then out-licenses the product to Dong Wha Pharm for the Korean market. 
  5. 3. Botanix's Share:
  6. Botanix is entitled to 25% of the royalties and milestone payments that Kaken receives from the Korean market sales. 

Key Points

  • No Upfront Payment Forecast: At the time of the agreement, Botanix did not provide a forecast amount for this revenue. 
  • Milestone and Royalty Payments: The payments Botanix receives will come from milestone payments for reaching sales targets and ongoing royalties based on the net sales of Ecclock in Korea. 
  • Information Availability: The precise amount Botanix will make is not currently public. 

In summary, Botanix earns its money through a percentage share of the payments Kaken receives from the Korean distributor, Dong Wha Pharm. 


15
Schwerms
Added 3 months ago

Thanks @Arizona that's a bit better than I thought, hopefully better pricing in Korea than Japan to help with the royalties.

12